Novartis’ BTK Inhibitor Outpaces Placebo in HS Trial
Remibrutinib, Novartis’ investigational oral Bruton’s tyrosine kinase (BTK) inhibitor, bested placebo in patients with moderate to severe hidradenitis suppurativa (HS), according to new data presented at the American Academy of Dermatology’s 2024 annual meeting in San Diego, CA. B cells and plasma cells are involved in HS lesions, and BTK plays a role in the […]